|
1
|
Resnikoff S, Pascolini D, Etya'ale D, et
al: Global data on visual impairment in the year 2002. Bull World
Health Organ. 82:844–851. 2004.PubMed/NCBI
|
|
2
|
Sheetz MJ and King GL: Molecular
understanding of hyperglycemia's adverse effects for diabetic
complications. JAMA. 288:2579–2588. 2002. View Article : Google Scholar
|
|
3
|
Stratton IM, Kohner EM, Aldington SJ, et
al: UKPDS 50: risk factors for incidence and progression of
retinopathy in Type II diabetes over 6 years from diagnosis.
Diabetologia. 44:156–163. 2001.PubMed/NCBI
|
|
4
|
Pettitt DJ, Saad MF, Bennett PH, Nelson RG
and Knowler WC: Familial predisposition to renal disease in two
generations of Pima Indians with type 2 (non-insulin-dependent)
diabetes mellitus. Diabetologia. 33:438–443. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
The Diabetes Control and Complications
Trial Research Group. Clustering of long-term complications in
families with diabetes in the diabetes control and complications
trial. Diabetes. 46:1829–1839. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Canani LH, Araki S, Warram JH and
Krolewski AS: Comment - to: Pinizzotto M, Castillo E, Fiaux M,
Temler E, Gaillard RC, Ruiz J (2001) Paraoxonase 2 polymorphisms
are associated with diabetic nephropathy in Type II diabetes.
Diabetologia 44: 104–107. Diabetologia. 44:1062–1064.
2001.PubMed/NCBI
|
|
7
|
Kao Y, Donaghue KC, Chan A, Bennetts BH,
Knight J and Silink M: Paraoxonase gene cluster is a genetic marker
for early microvascular complications in type 1 diabetes. Diabet
Med. 19:212–215. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pinizzotto M, Castillo E, Fiaux M, Temler
E, Gaillard RC and Ruiz J: Paraoxonase2 polymorphisms are
associated with nephropathy in Type II diabetes. Diabetologia.
44:104–107. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lyons TJ, Li W, Wells-Knecht MC and Jokl
R: Toxicity of mildly modified low-density lipoproteins to cultured
retinal capillary endothelial cells and pericytes. Diabetes.
43:1090–1095. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Morrison AC, Bare LA, Luke MM, et al:
Single nucleotide polymorphisms associated with coronary heart
disease predict incident ischemic stroke in the atherosclerosis
risk in communities study. Cerebrovasc Dis. 26:420–424. 2008.
View Article : Google Scholar
|
|
11
|
Luke MM, Lalouschek W, Rowland CM, et al:
Polymorphisms associated with both noncardioembolic stroke and
coronary heart disease: vienna stroke registry. Cerebrovasc Dis.
28:499–504. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Durrington PN, Mackness B and Mackness MI:
Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol.
21:473–480. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Araki S, Makita Y, Canani L, Ng D, Warram
JH and Krolewski AS: Polymorphisms of human paraoxonase 1 gene
(PON1) and susceptibility to diabetic nephropathy in type I
diabetes mellitus. Diabetologia. 43:1540–1543. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ergun MA, Yurtcu E, Demirci H, et al: PON1
55 and 192 gene polymorphisms in type 2 diabetes mellitus patients
in a Turkish population. Biochem Genet. 49:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kao YL, Donaghue K, Chan A, Knight J and
Silink M: A variant of paraoxonase (PON1) gene is associated with
diabetic retinopathy in IDDM. J Clin Endocrinol Metab.
83:2589–2592. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kordonouri O, James RW, Bennetts B, et al:
Modulation by blood glucose levels of activity and concentration of
paraoxonase in young patients with type 1 diabetes mellitus.
Metabolism. 50:657–660. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mackness B, McElduff P and Mackness MI:
The paraoxonase-2–310 polymorphism is associated with the presence
of microvascular complications in diabetes mellitus. J Intern Med.
258:363–368. 2005.
|
|
18
|
Murata M, Maruyama T, Suzuki Y, Saruta T
and Ikeda Y: Paraoxonase 1 Gln/Arg polymorphism is associated with
the risk of microangiopathy in Type 2 diabetes mellitus. Diabet
Med. 21:837–844. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tiwari AK, Prasad P, BKT, et al: Oxidative
stress pathway genes and chronic renal insufficiency in Asian
Indians with Type 2 diabetes. J Diabetes Complications. 23:102–111.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fleiss JL: The statistical basis of
meta-analysis. Stat Methods Med Res. 2:121–145. 1993. View Article : Google Scholar
|
|
21
|
Nivoit P, Wiernsperger N, Moulin P,
Lagarde M and Renaudin C: Effect of glycated LDL on microvascular
tone in mice: a comparative study with LDL modified in vitro or
isolated from diabetic patients. Diabetologia. 46:1550–1558. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mackness B, Durrington PN, Boulton AJ,
Hine D and Mackness MI: Serum paraoxonase activity in patients with
type 1 diabetes compared to healthy controls. Eur J Clin Invest.
32:259–264. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tsuzura S, Ikeda Y, Suehiro T, et al:
Correlation of plasma oxidized low-density lipoprotein levels to
vascular complications and human serum paraoxonase in patients with
type 2 diabetes. Metabolism. 53:297–302. 2004. View Article : Google Scholar
|
|
24
|
Humbert R, Adler DA, Disteche CM, Hassett
C, Omiecinski CJ and Furlong CE: The molecular basis of the human
serum paraoxonase activity polymorphism. Nat Genet. 3:73–76. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Garin MC, James RW, Dussoix P, et al:
Paraoxonase polymorphism Met-Leu54 is associated with modified
serum concentrations of the enzyme. A possible link between the
paraoxonase gene and increased risk of cardiovascular disease in
diabetes. J Clin Invest. 99:62–66. 1997. View Article : Google Scholar
|
